News
MDXXF
0.090
NaN%
--
Weekly Report: what happened at MDXXF last week (1109-1113)?
Weekly Report · 4d ago
Psychedelic: Definium Therapeutics narrows quarterly net loss
TipRanks · 11/12 15:00
PharmAla Signs MDMA Supply and Data Agreement for Danish PTSD Trial
TipRanks · 11/09 13:18
Weekly Report: what happened at MDXXF last week (1102-1106)?
Weekly Report · 11/09 09:36
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 11/05 15:50
PharmAla Partners with Corealis for GMP ALA-002 Manufacturing
TipRanks · 11/05 14:14
Weekly Report: what happened at MDXXF last week (1026-1030)?
Weekly Report · 11/02 09:36
Weekly Report: what happened at MDXXF last week (1019-1023)?
Weekly Report · 10/26 09:36
Weekly Report: what happened at MDXXF last week (1012-1016)?
Weekly Report · 10/19 09:36
Weekly Report: what happened at MDXXF last week (1005-1009)?
Weekly Report · 10/12 09:38
PharmAla taps Rua Bioscience to launch GMP-grade MDMA in New Zealand
TipRanks · 10/08 21:05
Weekly Report: what happened at MDXXF last week (0928-1002)?
Weekly Report · 10/05 09:38
Weekly Report: what happened at MDXXF last week (0921-0925)?
Weekly Report · 09/28 09:35
Weekly Report: what happened at MDXXF last week (0914-0918)?
Weekly Report · 09/21 09:36
PharmAla Biotech Overhauls Auditor and Bolsters Investor Outreach
TipRanks · 09/17 14:47
Weekly Report: what happened at MDXXF last week (0907-0911)?
Weekly Report · 09/14 09:38
Weekly Report: what happened at MDXXF last week (0831-0904)?
Weekly Report · 09/07 09:35
Weekly Report: what happened at MDXXF last week (0824-0828)?
Weekly Report · 08/31 09:38
Weekly Report: what happened at MDXXF last week (0817-0821)?
Weekly Report · 08/24 09:38
PharmAla Biotech Wins U.S. Patent, Retains APA-01 Rights and Hires Canaccord
TipRanks · 08/21 12:09
More
Webull provides a variety of real-time MDXXF stock news. You can receive the latest news about Pharmala Biotech through multiple platforms. This information may help you make smarter investment decisions.
About MDXXF
PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.